Blog
RSS FeedPosted by Michael Wonder on 08 Jul 2021
Health Canada approves Vyxeos, the first chemotherapy advance in over 40 years for adults with high-risk acute myeloid leukaemia
7 July 2021 - Jazz Pharmaceuticals today announced the Health Canada approval and availability of Vyxeos (daunorubicin and cytarabine liposome for ...
Posted by Michael Wonder on 06 Jul 2021
Knight Therapeutics announces Health Canada approval for Nerlynx (neratinib) to treat HER2 positive metastatic breast cancer
6 July 2021 - Knight Therapeutics announced today that Health Canada has approved Nerlynx (neratinib) in combination with capecitabine for the ...
Posted by Michael Wonder on 30 Jun 2021
Médunik Canada once again receives Notice of Compliance from Health Canada for Ruzurgi (amifampridine) following review ordered by court ruling
29 June 2021 - Médunik Canada is pleased to announce that Health Canada has reissued the approval (Notice of Compliance) ...
Posted by Michael Wonder on 29 Jun 2021
Medexus receives Notice of Compliance to commercialise Treosulfan in Canada
28 June 2021 - Medexus Pharmaceuticals today announced that it has received a Notice of Compliance from Health Canada to ...
Posted by Michael Wonder on 21 Jun 2021
Notice of Compliance with Conditions granted for Retevmo (selpercatinib), the first therapy in Canada specifically for patients with advanced RET driven lung and thyroid cancers
21 June 2021 - Conditional marketing authorisation based on data from LIBRETTO-001 Phase 1/2, the largest trial ever reported in patients ...
Posted by Michael Wonder on 18 Jun 2021
Health Canada grants marketing authorisation for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in people ages 12 and older who have at least one F508del mutation
18 June 2021 - Approximately 1,100 F/MF patients now eligible for a CFTR modulator to treat the underlying cause of their ...
Posted by Michael Wonder on 17 Jun 2021
Dupixent (dupilumab) pre-filled pen now available in Canada, providing convenient self-administration option for people with type 2 inflammatory diseases
17 June 2021 - The pre-filled pen offers an additional administration option for all Dupixent indications in patients aged 12 years ...
Posted by Michael Wonder on 10 Jun 2021
Health Canada grants interim order authorisation for casirivimab and imdevimab for the treatment of mild to moderate COVID-19
10 June 2021 - Interim data shows treatment with casirivimab and imdevimab resulted in a statistically significant reduction in viral ...
Posted by Michael Wonder on 09 Jun 2021
Paladin Labs announces approval of Wakix (pitolisant) in Canada
9 June 2021 - Paladin Labs today announced Health Canada's approval of Wakix (pitolisant) for the treatment of excessive daytime sleepiness ...
Posted by Michael Wonder on 08 Jun 2021
Health Canada approves AbbVie's Rinvoq (upadacitinib) for the treatment of adults with active psoriatic arthritis
7 June 2021 - Approval supported by efficacy and safety data of two pivotal Phase 3 trials in which Rinvoq demonstrated ...
Posted by Michael Wonder on 02 Jun 2021
Health Canada approves Opdivo (nivolumab) plus Yervoy (ipilimumab) as the first and only immunotherapy treatment for previously untreated unresectable malignant pleural mesothelioma
2 June 2021 - First new systemic therapy in more than 15 years for cancer related to asbestos exposure. ...
Posted by Michael Wonder on 01 Jun 2021
Health Canada approves Abecma (idecabtagene vicleucel), the first and only anti-BCMA CAR T cell therapy for relapsed and refractory multiple myeloma
31 May 2021 - Abecma is the first personalised cell therapy available to Canadian patients for the treatment of adults ...
Posted by Michael Wonder on 06 May 2021
Health Canada issues Notice of Compliance for Bausch Health's Bryhali
5 May 2021 - Bausch Health Canada today announced that Health Canada has approved the use of Bryhali (halobetasol propionate 0.01% ...
Posted by Michael Wonder on 30 Apr 2021
Ilaris receives Health Canada approval as first of its kind treatment for rare, inflammatory disorder, adult-onset Still's disease
29 April 2021 - The approval of Ilaris (canakinumab) in the treatment of adult-onset Still's disease brings hope for Canadians living ...
Posted by Michael Wonder on 28 Apr 2021
Rockwell Medical announces marketing approval of Triferic AVNU in Canada
27 March 2021 - Rockwell Medical today announced that Triferic AVNU (ferric pyrophosphate citrate injection) received a Notice of Compliance (marketing ...